Fig. 5: Assessment of the antinociceptive effect of the lead compounds by hot plate assay.
From: Exploiting the angiotensin-converting enzyme pathway to augment endogenous opioid signaling
Compounds (100 μg/mouse) were administered to the brain of 8-week old male ICR-CD1 mice by i.c.v. route according to the designed treatment regimen described above and %MPE of the compounds was recorded (n = 6–15 animals/group). A time-course of the antinociceptive effect of the lead compounds; captopril (A), thiorphan (B), and raloxifene (C), observed in the hot-plate assay is shown in the top panel. The Y-axis denotes %MPE and the X-axis shows the different time points. The bottom panel shows an analysis of %MPE for various treatment groups in the top panel observed at 15 min time point post compound administration. Data are shown as the mean ± SEM, with error bars representing SEM. One-way ANOVA followed by Sidak’s post hoc multiple comparison test was used to determine the statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Source data are provided in Supplementary Data 1.
